Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy

Table 2 Study population

		Frequency	Percent
Age	20.00	1	11.1
	25.00	1	11.1
	27.00	1	11.1
	29.00	1	11.1
	34.00	1	11.1
	37.00	1	11.1
	43.00	1	11.1
	51.00	1	11.1
Sex	M	8	100.0
	F	0	0
Cause of hypoxia	Cardiac arrest	1	12.5
	Cardiac arrest due to acute myocard infarction	3	37.5
	Cardiac arrest due to explosive devices injury	1	12.5
	Cardiac arrest due to multi-trauma	1	12.5
	Cardiac arrest, unkown ethiology	2	25.0
Duration of hypoxia	25.00	1	12.5
	30.00	1	12.5
	40.00	1	12.5
	45.00	3	37.5
	60.00	1	12.5
	75.00	1	12.5
Previous treatment	No	8	100.0
	Yes	0	0
Comorbidity	Atrial fibrilation	1	12.5
	No	7	87.5
Duration between hypoxia and first SCT	6.00	3	37.5
	10.00	1	12.5
	11.00	1	12.5
	18.00	2	25.0
	96.00	1	12.5

SCT: Stem cell therapy.